The Project ALS Therapeutics Core at Columbia

The Project ALS Therapeutics Core at Columbia is delivering better ALS drugs to patients. A program of @projectALSorg

[Project ALS @ProjectALSorg]

We’re excited to return after a short break and who better to bring us back than these 4 powerhouse women: @gwenpetersen7, Leah Stavenhagen, @shellymckenna, & Sally Stewart.

Join us for Project ALS Research Live on Tues, June 1, 1pm ET.

Register here: https://t.co/CQNHdWhWRw

[Project ALS @ProjectALSorg]

Project ALS mourns the passing of the multi-Tony-nominated actress and singer Rebecca Luker from ALS. Rebecca was diagnosed with ALS out of nowhere last year—and immediately rallied her Broadway community, leading the charge for ALS research and advocacy. She changed the world.

[Project ALS @ProjectALSorg]

Project ALS mourns the passing of a great leader, Chris Combs. Love to Team Chris Combs.

[Project ALS @ProjectALSorg]

Through the generous support of the Wasserman family and Project ALS, the lab of Dr. Alejandro Chavez is pursuing an ambitious project to develop broad acting ALS therapeutics.

Read our newest blog post to learn more: https://t.co/cW1OfGMsyc

[Ben Stiller @BenStiller]

Thanks @RebeccaJLuker for making a huge difference in the path to a cure for #ALS and your courage in telling your story. Wishing you strength and love. @ProjectALSorg

[Project ALS @ProjectALSorg]

For the record: ALS is still barbaric, the lack of meaningful treatments is still unacceptable, and we will fight with incredible leaders like @sandymorris333 until Jenifer’s words no longer resonate.

[Project ALS @ProjectALSorg]

Project ALS is proud to support this work, led by Drs. Valeria Gerbino and Tom Maniatis (Columbia), through our collaborative effort to understand the role of autophagy in ALS. Through the @projectalsCORE we are applying these important findings to therapeutic discovery for ALS.

[The Project ALS Therapeutics Core at Columbia @projectalsCORE]

We are committed to moving Prosetin to clinical trial as soon as possible. Please send us any questions—we will go live next week to answer them.

[Project ALS @ProjectALSorg]

The ALS community is all too familiar with earth-shattering health crises like COVID-19, and Project ALS remains committed to moving our lead drug candidate, Prosetin, to clinical trial as quickly as possible. Watch the full update from our team here:

https://t.co/DvpJLF3dzk

[PVPHS @pvphsasb]

Today our Panther Family came together in support of Eric Stevens and @stevens_nation and raised $43,000 for #ProjectALS. We must #AxeALS for all 30,000 Americans living with ALS 💙🙏🏻

[The Project ALS Therapeutics Core at Columbia @projectalsCORE]

Join the Prosetin team on Feb 4th at 1pm EST! Register here: https://t.co/IaryFiwhdZ

[Project ALS @ProjectALSorg]

Click here to register: https://t.co/HcF6aM65Vj

#Prosetin2020

[The Project ALS Therapeutics Core at Columbia @projectalsCORE]

@als_out Hi Eric, we know this is a little late but someone from Project ALS would be happy to come and speak to the group - we are not far away! You know how to reach us if you'd like to set it up.

[The Project ALS Therapeutics Core at Columbia @projectalsCORE]

We'll be working with Dr. Elyaman to develop: (1) more useful biomarkers for ALS—i.e. more disease-specific than what's currently validated—and (2) targeted treatments that hit ALS-specific inflammatory/immune pathways.

[The Project ALS Therapeutics Core at Columbia @projectalsCORE]

We know that neurodegenerative diseases like ALS, Alzheimer's, Parkinson’s, & even MS have common features, like neuroinflammation and immune system dysfunction.

[The Project ALS Therapeutics Core at Columbia @projectalsCORE]

THE CORE is excited to work with Wassim Elyaman, PhD—an expert on neuroinflammation and immunity in Alzheimer's and MS—to better understand the specifics of what's happening to these mechanisms in ALS.

[Steve Gleason - "Live Impossible" @SteveGleason]

My statement on the Congressional Gold Medal.
-SG

[The Project ALS Therapeutics Core at Columbia @projectalsCORE]

@nadia_sethi @alsadvocacy @ProjectALSorg Thank you Nadia!

[The Project ALS Therapeutics Core at Columbia @projectalsCORE]

A complex topic—but at baseline, we support any legislation that might move meaningful treatments to #ALS patients sooner.

[ALS Advocacy @alsadvocacy]

This is interesting. What therapies might we have today if we had a conditional approval path yrs ago? Could confirmatory studies actually find responder groups? Would today's ALS therapies actually be less expensive had there been confirmatory studies? https://t.co/3pWv0kXBVk

[The Project ALS Therapeutics Core at Columbia @projectalsCORE]

@alsadvocacy In theory, drugs approved via AA require a Ph 4 confirmatory trial to stay on the market. Looks like it doesn't always play out that way in practice: https://t.co/iidmXrbNFB

[The Project ALS Therapeutics Core at Columbia @projectalsCORE]

@myalsworld The Nurown Ph 3 trial should be very helpful in starting to answer that question for MCP-1...but we need to be measuring many promising biomarkers across ALL ALS clinical trials so we can really ID the best markers of the disease.

[The Project ALS Therapeutics Core at Columbia @projectalsCORE]

@myalsworld Hi—great question! We should host a livestream about this topic, as it's nuanced. 30,000ft answer: yes, we will use MCP-1 & more (like NF-L)! But those are not direct markers of ALS—we have more work to do to validate that a change in MCP-1=an impact on a person's ALS.